Let's Learn About CRC
CtDNA Testing For CRC
Immunotherapy
Clinical Trials
BRAF Talks
KRAS Talks
All Things Liver
The Conference Center: Research Roundups
Rectal Cancer
Anal Cancer
Practical Considerations
Questions? Feedback?

ASCO 2021 Poster Walks

Many thanks to Drs. Kurzrock, Sanford, Jethwa & Loree for taking the time to share their expertise for these Poster Walks!

Session 1:

  1.  LEAP 005 trial: Phase 2 Lenvatinib plus Pembrolizumab 
  2. Neoadjuvant chemo to improve colon cancer survival in resectable metastatic colon cancer- A real world NCDB analysis

Dr. Razelle Kurzrock, a precision medicine expert, discusses the LEAP 005 trial and the real world study on the role of neoadjuvant chemo in resectable metastatic CRC.  Colorectal cancer patients from COLONTOWN participate in this in-depth conversation.

We also have a follow-up conversation in COLONTOWN with our clinical trials curator Adrian Terek; if you are a member  of our MSS trials neighborhood be sure to check out that discussion.

Session 2.:

  1. CtDNA to predict recurrence of metastatic CRC following surgery or radiation
  2. Phase 2 PANDORA trial: Capecitabine+ concomitant RT followed by durvalumab as preoperative treatment in rectal cancer

Dr. Nina Sanford, a radiation oncologist, discusses data from an observational study to assess the value of ctDNA (liquid biopsy) in predicting recurrence of metastatic CRC after surgery or radiation. The 2nd poster covers the PANDORA trial for rectal cancer.

Session 3:

  1. Survival and organ preservation according to clinical response after TNT in locally advanced rectal cancer patients, a secondary analysis from the OPRA trial 
  2. Phase 2 PANDORA trial: Capecitabine+ concomitant RT followed by durvalumab as preoperative treatment in rectal cancer

Dr. Krishan Jethwa, a radiation oncologist, discusses the OPRA trial, and also reviews proton therapy for rectal cancer in this conversation. He has a slightly different take on the PANDORA trial.